Header Logo
Last Name


InstitutionMD Anderson
DepartmentThoracic Head & Neck Medical Oncology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Dragnev KH, Ma T, Cyrus J, Galimberti F, Memoli V, Busch AM, Tsongalis GJ, Seltzer M, Johnstone D, Erkmen CP, Nugent W, Rigas JR, Liu X, Freemantle SJ, Kurie JM, Waxman S, Dmitrovsky E. Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer Prev Res (Phila). 2011 Jun; 4(6):818-28. PMID: 21636548.
      View in: PubMed
    2. Liu X, Sempere LF, Guo Y, Korc M, Kauppinen S, Freemantle SJ, Dmitrovsky E. Involvement of microRNAs in lung cancer biology and therapy. Transl Res. 2011 Apr; 157(4):200-8. PMID: 21420030.
      View in: PubMed
    3. Guo Y, Dolinko AV, Chinyengetere F, Stanton B, Bomberger JM, Demidenko E, Zhou DC, Gallagher R, Ma T, Galimberti F, Liu X, Sekula D, Freemantle S, Dmitrovsky E. Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARa and inhibits the growth of acute promyelocytic leukemia. Cancer Res. 2010 Dec 01; 70(23):9875-85. PMID: 20935222.
      View in: PubMed
    4. Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, Demidenko E, Korc M, Shi W, Preis M, Dragnev KH, Li H, Direnzo J, Bak M, Freemantle SJ, Kauppinen S, Dmitrovsky E. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest. 2010 Apr; 120(4):1298-309. PMID: 20237410.
      View in: PubMed
    5. Galimberti F, Thompson SL, Liu X, Li H, Memoli V, Green SR, DiRenzo J, Greninger P, Sharma SV, Settleman J, Compton DA, Dmitrovsky E. Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe. Clin Cancer Res. 2010 Jan 01; 16(1):109-20. PMID: 20028770.
      View in: PubMed
    6. Sempere LF, Liu X, Dmitrovsky E. Tumor-suppressive microRNAs in Lung cancer: diagnostic and therapeutic opportunities. ScientificWorldJournal. 2009 Jul 13; 9:626-8. PMID: 19618089.
      View in: PubMed
    7. Liu X, Sempere LF, Galimberti F, Freemantle SJ, Black C, Dragnev KH, Ma Y, Fiering S, Memoli V, Li H, DiRenzo J, Korc M, Cole CN, Bak M, Kauppinen S, Dmitrovsky E. Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res. 2009 Feb 15; 15(4):1177-83. PMID: 19228723.
      View in: PubMed
    8. Feng Q, Sekula D, Guo Y, Liu X, Black CC, Galimberti F, Shah SJ, Sempere LF, Memoli V, Andersen JB, Hassel BA, Dragnev K, Dmitrovsky E. UBE1L causes lung cancer growth suppression by targeting cyclin D1. Mol Cancer Ther. 2008 Dec; 7(12):3780-8. PMID: 19074853.
      View in: PubMed
    9. Liby K, Black CC, Royce DB, Williams CR, Risingsong R, Yore MM, Liu X, Honda T, Gribble GW, Lamph WW, Sporn TA, Dmitrovsky E, Sporn MB. The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. Mol Cancer Ther. 2008 May; 7(5):1251-7. PMID: 18483313.
      View in: PubMed
    10. Freemantle SJ, Liu X, Feng Q, Galimberti F, Blumen S, Sekula D, Kitareewan S, Dragnev KH, Dmitrovsky E. Cyclin degradation for cancer therapy and chemoprevention. J Cell Biochem. 2007 Nov 01; 102(4):869-77. PMID: 17868090.
      View in: PubMed
    11. Ma Y, Fiering S, Black C, Liu X, Yuan Z, Memoli VA, Robbins DJ, Bentley HA, Tsongalis GJ, Demidenko E, Freemantle SJ, Dmitrovsky E. Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci U S A. 2007 Mar 06; 104(10):4089-94. PMID: 17360482.
      View in: PubMed
    12. The ISG15-specific protease USP18 regulates stability of PTEN. Oncotarget. 8:3-14.
    13. Dinaciclib induces anaphase catastrophe in lung cancer cells via inhibition of cyclin-dependent kinases 1 and 2. Molecular Cancer Therapeutics. 15:2758-2766.
    14. The myb-p300 interaction is a novel molecular pharmacologic target. Molecular Cancer Therapeutics. 14:1273-1275.
    15. GOS2 suppresses oncogenic transformation by repressing a MYC-regulated transcriptional program. Cancer Research. 76:1204-1213.
    LIU's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Co-Authors Expand Description
    Similar People Expand Description
    Same Department Expand Description